Elevance Health, Inc. (ELV) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript

Elevance Health discussed its CMS Medicare Advantage sanctions update at Goldman Sachs, saying it is working through remaining actions toward a full regulatory resolution. The key issue is whether CMS will confirm all required remedies have been addressed, which would likely leave MA enrollment and margins materially unchanged. The remarks were largely procedural and do not indicate a new financial impact.

Analysis

The near-term setup for ELV is less about earnings power today and more about how quickly management can convert regulatory uncertainty into a clean operating narrative. In managed care, sanction overhangs usually compress the multiple more than the underlying fundamentals, so a credible path to closure should mechanically remove a valuation discount even if operating assumptions barely change. The key second-order effect is on capital allocation: once the market believes the issue is fully contained, the stock can rerate faster than the underlying MA economics improve.

The main beneficiary is ELV itself, but the broader loser is any MA peer still carrying compliance or utilization-review scrutiny, because investors will become less forgiving on governance risk after one name clears the tape. A resolution here could also tighten competitive intensity in Medicare Advantage if ELV is able to re-accelerate enrollment while rivals remain more cautious on growth or pricing. That creates a subtle margin-share tradeoff: the first mover to regain trust can take lives at better economics than peers that are still de-risking.

The contrarian risk is that the market may be too focused on a binary “sanctions cleared” outcome and underweight the implementation lag. Even with favorable CMS confirmation, remediation can consume management bandwidth for quarters, and any minor follow-on request from regulators can keep the discount alive. In other words, the stock can respond immediately, but the durable upside likely requires several reporting cycles of clean execution rather than just one headline.

For positioning, the cleanest expression is to own ELV on weakness into the regulatory resolution window, not after the headline has already been validated by the market. The asymmetric trade is a rerating play with limited fundamental downside if the remedies are accepted, but a meaningful gap-down if CMS delays closure or asks for additional actions. The probability-weighted setup favors a medium-term long, while the short-side opportunity is in peers with similar compliance exposure or weaker disclosure quality.

Key Decisions for Investors

• Buy ELV on any pullback tied to CMS headline risk; hold 1-3 months for multiple compression to unwind if resolution is confirmed. Risk/reward is favorable because the downside is mostly process risk, while upside comes from a re-rating rather than earnings revision.
• Pair trade: long ELV / short a basket of managed care peers with higher regulatory or governance skepticism over the next 1-2 quarters. The trade captures relative rerating if ELV clears the overhang while the basket remains discounted.
• If ELV spikes on a formal CMS closure, sell 25-50% into strength and keep the balance for execution follow-through over the next two earnings prints. This avoids giving back gains if remediation proves slower than the headline implies.
• For options, consider ELV call spreads 3-6 months out rather than outright calls. That structure expresses a rerating view while limiting premium decay if the market waits for evidence instead of paying immediately.